Skip to main content
. 2026 Jan 15;18(2):264. doi: 10.3390/cancers18020264
ADT androgen deprivation therapy
LPA life-prolonging agent
mCRPC metastatic castration resistant prostate cancer
mHSPC  metastatic hormone-sensitive prostate cancer
PC prostate cancer
piOS post-infection overall survival
piPFS post-infection progression-free survival
SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2